Emergency Medical Research Journals

Emergency Med

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Stryjewski ME et al. – Linezolid, daptomycin and tigecycline have been approved during the last decade to treat infections due to MRSA. Although these agents are extremely valuable in the fight against MRSA, each one has limitations. New lypoglycopeptides (telavancin, dalbavancin and oritavancin) are in advanced phase of clinical development. Similarly, new broad–spectrum cephalosporins active against MRSA (e.g. ceftobiprole and ceftaroline) and a new dihydrofolate reductase inhibitor (iclaprim) are in or have completed phase 3 studies.

Today in Clinical Pharmacology...keeping you current

Propylene Glycol Accumulation in Critically Ill Patients Receiving Continuous Intravenous Lorazepam Infusions
Annals of Pharmacotherapy, 11/25/09

Pharmacotherapy for acute pancreatitis
Expert Opinion in Pharmacotherapy, 11/24/09

Ascorbic Acid Potentiation of Arsenic Trioxide Anticancer Activity Against Acute Promyelocytic Leukemia
Archives of Drug Information, 11/24/09

Today in Infectious Disease...keeping you current

Emergency Influenza Drug
JAMA, 11/25/09

Emerging Role of Candida in Deep Sternal Wound Infection
Annals of Thoracic Surgery, 11/25/09

Will Routine Annual Influenza Prevention and Control Systems Serve the United States Well in a Pandemic
Disaster Medicine and Public Health Preparedness, 11/25/09

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Send this Summary to a Colleague

Enter email address